menu

Slide

Investments in unique diagnostic technologies for the era of precision medicine

Scroll Down
Scroll Down
Hummingbird Diagnostics Announces Publication Evaluating miR-Blood’s Small RNA Expression Dataset Capabilities in Nature’s Scientific Data

READ MORE

Hummingbird Diagnostics GmbH to Unveil Pioneering Alzheimer’s Disease Biomarker Research at CTAD Conference

READ MORE

Lung Cancer Data Heralds Shift for Hummingbird Diagnostics to Focus on Early Detection

READ MORE

Hummingbird Diagnostics Announces Publication of miLung Small RNA-Based Blood Test for Early Detection of Lung Cancer in the Journal of Thoracic Oncology

READ MORE

GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

DISCLAIMER